Asklepion   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Baltimore MD United States (2006)

Organization Overview

First Clinical Trial
2006
NCT00428935
First Marketed Drug
2015
cholic acid (cholbam)
First NDA Approval
2015
cholic acid (cholbam)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Asklepion Pharmaceuticals, LLC | Asklepios Biopharmaceutical, Inc. | RTRX